JP2023040169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023040169A5 JP2023040169A5 JP2023001554A JP2023001554A JP2023040169A5 JP 2023040169 A5 JP2023040169 A5 JP 2023040169A5 JP 2023001554 A JP2023001554 A JP 2023001554A JP 2023001554 A JP2023001554 A JP 2023001554A JP 2023040169 A5 JP2023040169 A5 JP 2023040169A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- replaced
- asn
- lys
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 16
- 235000001014 amino acid Nutrition 0.000 claims 8
- 238000006467 substitution reaction Methods 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims 3
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 claims 3
- 238000012423 maintenance Methods 0.000 claims 3
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000001815 biotherapy Methods 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 238000002650 immunosuppressive therapy Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- -1 cysteine amino acids Chemical group 0.000 claims 1
- 229960000860 dapsone Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229940027941 immunoglobulin g Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 150000002617 leukotrienes Chemical class 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229940014456 mycophenolate Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229940125379 topical corticosteroid Drugs 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GBGB1706404.9A GB201706404D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GB1706404.9 | 2017-04-21 | ||
| GB1706406.4 | 2017-04-21 | ||
| GB1706452.8 | 2017-04-24 | ||
| GBGB1706452.8A GB201706452D0 (en) | 2017-04-24 | 2017-04-24 | Method of treatment |
| JP2019556794A JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| PCT/EP2018/060241 WO2018193122A1 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Division JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023040169A JP2023040169A (ja) | 2023-03-22 |
| JP2023040169A5 true JP2023040169A5 (enExample) | 2023-10-11 |
| JP7600278B2 JP7600278B2 (ja) | 2024-12-16 |
Family
ID=62235916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
| JP2023001554A Active JP7600278B2 (ja) | 2017-04-21 | 2023-01-10 | 自己免疫性水疱症の治療のためのコバーシン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556794A Active JP7209637B2 (ja) | 2017-04-21 | 2018-04-20 | 自己免疫性水疱症の治療のためのコバーシン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11730792B2 (enExample) |
| EP (2) | EP4275696A1 (enExample) |
| JP (2) | JP7209637B2 (enExample) |
| KR (1) | KR102656199B1 (enExample) |
| CN (1) | CN110896606B (enExample) |
| AU (1) | AU2018253962B2 (enExample) |
| CA (1) | CA3059657A1 (enExample) |
| DK (1) | DK3612208T5 (enExample) |
| ES (1) | ES2945433T3 (enExample) |
| IL (1) | IL269895B2 (enExample) |
| PL (1) | PL3612208T3 (enExample) |
| WO (1) | WO2018193122A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| EP3612206A1 (en) * | 2017-04-21 | 2020-02-26 | Volution Immuno Pharmaceuticals SA | Coversin for the treatment of cicatrising eye inflammatory disorders |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| DK3612208T5 (da) | 2017-04-21 | 2024-09-02 | Volution Immuno Pharmaceuticals Sa | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse |
| US20220047673A1 (en) * | 2018-09-10 | 2022-02-17 | Volution Immuno Pharmaceuticals Sa | Coversin for Use in the Treatment of Rheumatic Diseases |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| AU2019468121A1 (en) | 2019-09-27 | 2022-05-12 | Volution Immuno Pharmaceuticals Sa | Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) |
| GB202218084D0 (en) * | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| MXPA05012880A (es) | 2003-06-02 | 2006-02-22 | Evolutec Ltd | Inhibidores de complemento. |
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007095230A2 (en) | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
| JP2010502687A (ja) | 2006-09-08 | 2010-01-28 | ヴァーレイ・リミテッド | 呼吸器疾患の治療方法 |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| EA200901211A1 (ru) | 2007-03-22 | 2010-04-30 | Новартис Аг | Антигены белка с5 и их применение |
| PL2173890T3 (pl) * | 2007-06-21 | 2011-07-29 | Univ Muenchen Tech | Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| WO2011056972A2 (en) * | 2009-11-04 | 2011-05-12 | Case Western Reserve University | Compositions and methods of treating a t cell mediated disorder |
| MX2011003328A (es) * | 2008-10-06 | 2011-06-20 | Carolus Therapeutics Inc | Metodos para tratar inflamacion. |
| GB0906779D0 (en) * | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| NZ597259A (en) * | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| CN102762223B (zh) | 2010-01-08 | 2014-09-03 | 沃卢申伊谬诺制药公司 | 用于治疗呼吸道病毒性感染的ev576 |
| ES3044832T3 (en) | 2011-06-22 | 2025-11-27 | Apellis Pharmaceuticals Inc | Methods of treating chronic disorders with complement inhibitors |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| US20160051673A1 (en) * | 2013-03-29 | 2016-02-25 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| GB201410031D0 (en) * | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2016198133A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| WO2016094834A2 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
| US9937222B2 (en) * | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| EP3307316A1 (en) * | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP4462121A3 (en) | 2015-09-11 | 2025-01-22 | Alexion Pharmaceuticals, Inc. | Recombinant glycosylated eculizumab and eculizumab variants |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| EP3612206A1 (en) | 2017-04-21 | 2020-02-26 | Volution Immuno Pharmaceuticals SA | Coversin for the treatment of cicatrising eye inflammatory disorders |
| DK3612208T5 (da) | 2017-04-21 | 2024-09-02 | Volution Immuno Pharmaceuticals Sa | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse |
-
2018
- 2018-04-20 DK DK18726731.5T patent/DK3612208T5/da active
- 2018-04-20 EP EP23166056.4A patent/EP4275696A1/en active Pending
- 2018-04-20 KR KR1020197031711A patent/KR102656199B1/ko active Active
- 2018-04-20 IL IL269895A patent/IL269895B2/en unknown
- 2018-04-20 WO PCT/EP2018/060241 patent/WO2018193122A1/en not_active Ceased
- 2018-04-20 CN CN201880041710.5A patent/CN110896606B/zh active Active
- 2018-04-20 JP JP2019556794A patent/JP7209637B2/ja active Active
- 2018-04-20 PL PL18726731.5T patent/PL3612208T3/pl unknown
- 2018-04-20 ES ES18726731T patent/ES2945433T3/es active Active
- 2018-04-20 CA CA3059657A patent/CA3059657A1/en active Pending
- 2018-04-20 US US16/603,352 patent/US11730792B2/en active Active
- 2018-04-20 EP EP18726731.5A patent/EP3612208B1/en active Active
- 2018-04-20 AU AU2018253962A patent/AU2018253962B2/en active Active
-
2023
- 2023-01-10 JP JP2023001554A patent/JP7600278B2/ja active Active
- 2023-06-09 US US18/332,191 patent/US20240009270A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023040169A5 (enExample) | ||
| TWI436776B (zh) | Ｆｇｆ２１突變體及其用途 | |
| JP2024150674A5 (enExample) | ||
| JP6809789B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP4398644B2 (ja) | ＥｒｂＢ界面ペプチド擬態およびその使用方法 | |
| JP2017538395A5 (enExample) | ||
| JP7189142B2 (ja) | 抗ヒトアネキシンａ１抗体 | |
| JPWO2019140050A5 (enExample) | ||
| KR20080055932A (ko) | 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제 | |
| JPH07504883A (ja) | リボソーム不活性化タンパク質を含む物質およびそれを調製ならびに使用する方法 | |
| JP2018538356A5 (enExample) | ||
| JP2020517627A5 (enExample) | ||
| JP2021512159A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| TW201143789A (en) | Antigen binding proteins | |
| JP2023503472A (ja) | 長時間作用型ｇｄｆ１５融合タンパク質およびそれを含む医薬組成物 | |
| WO2023061472A1 (zh) | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2021116182A5 (enExample) | ||
| JPWO2020041604A5 (enExample) | ||
| JP2021522231A (ja) | チオエーテル環状ペプチドアミリン受容体調節因子 | |
| JPH08511542A (ja) | コイル状−コイルステムループ鋳型 | |
| CN111234015A (zh) | 用于延长药物半衰期的抗体、其融合蛋白和应用 | |
| JPWO2022129560A5 (enExample) | ||
| JPWO2021052349A5 (enExample) | ||
| JPWO2020216513A5 (enExample) |